Wallukat G, Wollenberger A, Morwinski R, Pitschner H F
Cardiology, Max Delbrück Centre for Molecular Medicine, Berlin-Buch, Germany.
J Mol Cell Cardiol. 1995 Jan;27(1):397-406. doi: 10.1016/s0022-2828(08)80036-3.
In a preceding communication (Wallukat et al., 1992, Z Kardiol 81 [Suppl. 4]: 79-83), it was reported that synthetic peptides, corresponding in amino acid sequence to either the first or the second extracellular loop of the human beta 1-adrenoceptor, selectively suppressed the metoprolol- and bisoprolol-sensitive positive chronotropic action exerted in cultures of beating neonatal rat cardiomyocytes by the serum immunoglobulin fraction of patients with myocarditis and idiopathic dilated cardiomyopathy (DCM) and by affinity-purified autoantibodies from that fraction. These observations added to existing evidence that these antibodies were directed against the beta 1-adrenoceptor and might thus contribute to the harmful chronic cardiac adrenergic drive to which patients with DCM are believed to be exposed. Specifically, they pointed to the putative first and second extracellular loops of this receptor (these loops are each identical in man and the rat) as the sites of epitopes recognized by the chronotropically active, beta 1-agonistic autoantibodies. Now we report on the mapping of these epitopes with the help of two series of short synthetic overlap peptides, one series forming part of the first and the other of the second extracellular loop of the beta 1-adrenoceptor. Inhibition of the positive chronotropic response of cultured rat cardiomyocytes to the anti-beta 1-receptor autoantibodies (EC50 = 0.14 +/- 0.01 nM) from the serum immunoglobulin fraction of patients with DCM was taken as reflecting the neutralization of these antibodies by a particular overlap peptide. In this way the sequences S-F-F-C-E-L (residues 129-134) and A-R-R-C-Y-N-D (residues 206-212) emerged as the dominant epitopes in the first and second extracellular loops, respectively, followed with respect to neutralizing ability by the first loop sequence E-Y-G-S-F-F (residues 126-131) and the second loop sequences H-W-W-R-A-E (residues 197-202) and P-K-C-C-D-F (residues 213-218). Synthetic peptides corresponding to the sequences of the third extracellular loop of the beta 1-receptor (residues 346-356) and of the second extracellular loop of the human beta 2-receptor (residues 172-197) failed to neutralize the beta 1-agonistic autoantibodies. Using dithiothreitol as a reducing agent a disulfide bridge between cysteine 132 in the first and cysteine 209 in the second extracellular loop was considered to be essential for the chronotropic action of these autoantibodies.(ABSTRACT TRUNCATED AT 400 WORDS)
在之前的一篇通讯文章中(Wallukat等人,1992年,《心脏病学杂志》81[增刊4]:79 - 83),据报道,氨基酸序列与人β1 - 肾上腺素能受体的第一或第二细胞外环相对应的合成肽,能选择性地抑制美托洛尔和比索洛尔敏感的正性变时作用,这种作用由心肌炎和特发性扩张型心肌病(DCM)患者的血清免疫球蛋白组分以及从该组分中亲和纯化的自身抗体在新生大鼠搏动心肌细胞培养物中产生。这些观察结果进一步证明了这些抗体是针对β1 - 肾上腺素能受体的,因此可能促成了DCM患者被认为所暴露的有害慢性心脏肾上腺素能驱动。具体而言,它们指出该受体假定的第一和第二细胞外环(这些环在人和大鼠中是相同的)是变时活性β1 - 激动性自身抗体识别的表位部位。现在我们报告借助两组短的合成重叠肽对这些表位进行定位,一组肽构成β1 - 肾上腺素能受体第一细胞外环的一部分,另一组构成第二细胞外环的一部分。将培养的大鼠心肌细胞对来自DCM患者血清免疫球蛋白组分的抗β1 - 受体自身抗体(EC50 = 0.14±0.01 nM)的正性变时反应的抑制作为特定重叠肽对这些抗体中和作用的反映。通过这种方式,序列S - F - F - C - E - L(残基129 - 134)和A - R - R - C - Y - N - D(残基206 - 212)分别成为第一和第二细胞外环中的主要表位,随后在中和能力方面依次是第一环序列E - Y - G - S - F - F(残基126 - 131)以及第二环序列H - W - W - R - A - E(残基197 - 202)和P - K - C - C - D - F(残基213 - 218)。与β1 - 受体第三细胞外环序列(残基346 - 356)和人β2 - 受体第二细胞外环序列(残基172 - 197)相对应的合成肽未能中和β1 - 激动性自身抗体。使用二硫苏糖醇作为还原剂,第一细胞外环中的半胱氨酸132与第二细胞外环中的半胱氨酸209之间的二硫键被认为是这些自身抗体变时作用所必需的。(摘要截短至400字)